title: High IFIT1 expression predicts improved clinical outcome, and IFIT1 along with MGMT more accurately predicts prognosis in newly diagnosed glioblastoma.
abstract: Interferon-induced protein with tetratricopeptide repeat 1 (IFIT1) plays a key role in growth suppression and apoptosis promotion in cancer cells. Interferon was reported to induce the expression of IFIT1 and inhibit the expression of O-6-methylguanine-DNA methyltransferase (MGMT).This study aimed to investigate the expression of IFIT1, the correlation between IFIT1 and MGMT, and their impact on the clinical outcome in newly diagnosed glioblastoma. The expression of IFIT1 and MGMT and their correlation were investigated in the tumor tissues from 70 patients with newly diagnosed glioblastoma. The effects on progression-free survival and overall survival were evaluated. Of 70 cases, 57 (81.4%) tissue samples showed high expression of IFIT1 by immunostaining. The χ(2) test indicated that the expression of IFIT1 and MGMT was negatively correlated (r = -0.288, P = .016). Univariate and multivariate analyses confirmed high IFIT1 expression as a favorable prognostic indicator for progression-free survival (P = .005 and .017) and overall survival (P = .001 and .001), respectively. Patients with 2 favorable factors (high IFIT1 and low MGMT) had an improved prognosis as compared with others. The results demonstrated significantly increased expression of IFIT1 in newly diagnosed glioblastoma tissue. The negative correlation between IFIT1 and MGMT expression may be triggered by interferon. High IFIT1 can be a predictive biomarker of favorable clinical outcome, and IFIT1 along with MGMT more accurately predicts prognosis in newly diagnosed glioblastoma.
authors.affiliation: The First Clinical Medical College of Fujian Medical University, Fuzhou, Fujian 350005, China.
authors.forename: Jin-Feng
authors.initials: JF
authors.lastname: Zhang
authors.affiliation: Department of Neurosurgery, the First Affiliated Hospital of Fujian Medical University, Fuzhou, Fujian 350005, China.
authors.forename: Yao
authors.initials: Y
authors.lastname: Chen
authors.affiliation: Department of Neurosurgery, Zhangzhou Affiliated Hospital of Fujian Medical University, Zhangzhou, Fujian 363000, China.
authors.forename: Guo-Shi
authors.initials: GS
authors.lastname: Lin
authors.affiliation: Department of Neurosurgery, the First Affiliated Hospital of Fujian Medical University, Fuzhou, Fujian 350005, China.
authors.forename: Jian-Dong
authors.initials: JD
authors.lastname: Zhang
authors.affiliation: Department of Neurosurgery, the First Affiliated Hospital of Fujian Medical University, Fuzhou, Fujian 350005, China.
authors.forename: Wen-Long
authors.initials: WL
authors.lastname: Tang
authors.affiliation: Department of Neurosurgery, the Affiliated Hospital of Putian University, Putian, Fujian 351100, China.
authors.forename: Jian-Huang
authors.initials: JH
authors.lastname: Huang
authors.affiliation: Xianyou County Hospital of Fujian Province, Xianyou, Fujian 351200, China.
authors.forename: Jin-Shou
authors.initials: JS
authors.lastname: Chen
authors.affiliation: Department of Pathology, the First Affiliated Hospital of Fujian Medical University, Fuzhou Fujian, 350005, China.
authors.forename: Xing-Fu
authors.initials: XF
authors.lastname: Wang
authors.affiliation: The First Clinical Medical College of Fujian Medical University, Fuzhou, Fujian 350005, China; Department of Neurosurgery, Beijing Sanbo Brain Hospital, Capital Medical University, Beijing 100093, China. Electronic address: lzx1967@sina.com.
authors.forename: Zhi-Xiong
authors.initials: ZX
authors.lastname: Lin
mesh_terms: D048868:Adaptor Proteins, Signal Transducing; D014408:Biomarkers, Tumor / Q000032:analysis*; D001932:Brain Neoplasms / Q000201:enzymology* / Q000401:mortality / Q000473:pathology / Q000628:therapy; D002352:Carrier Proteins / Q000032:analysis*; D016009:Chi-Square Distribution; D015254:DNA Modification Methylases / Q000032:analysis*; D045643:DNA Repair Enzymes / Q000032:analysis*; D018572:Disease-Free Survival; D005260:Female; D005909:Glioblastoma / Q000201:enzymology* / Q000401:mortality / Q000473:pathology / Q000628:therapy; D006801:Humans; D007150:Immunohistochemistry; D053208:Kaplan-Meier Estimate; D019394:Ki-67 Antigen / Q000032:analysis; D008297:Male; D008875:Middle Aged; D015999:Multivariate Analysis; D011237:Predictive Value of Tests; D016601:RNA-Binding Proteins; D012189:Retrospective Studies; D012307:Risk Factors; D013997:Time Factors; D016896:Treatment Outcome; D025521:Tumor Suppressor Proteins / Q000032:analysis*; D015854:Up-Regulation
chemical_list: D048868:Adaptor Proteins, Signal Transducing; D014408:Biomarkers, Tumor; D002352:Carrier Proteins; C484290:IFIT1 protein, human; D019394:Ki-67 Antigen; D016601:RNA-Binding Proteins; D025521:Tumor Suppressor Proteins; D015254:DNA Modification Methylases; C515491:MGMT protein, human; D045643:DNA Repair Enzymes
keywords: Glioblastoma; IFIT1; IFN; MGMT; Prognosis